Review
Copyright ©The Author(s) 2016.
World J Gastrointest Oncol. Apr 15, 2016; 8(4): 389-401
Published online Apr 15, 2016. doi: 10.4251/wjgo.v8.i4.389
Table 1 Ongoing phaseIII trials in gastro-entero-pancreatic neuroendocrine tumours
ClinicalTrials.gov IdentifierInvestigated drugTargetType of enrolled pts
NCT00171873Octreotide LAR 30 mgSSTRLocally inoperable or metastatic well differentiated NETs of the midgut Naïve pts
NCT01524783Everolimus plus BSC vs PBO plus BSCmTORUnresectable or metastatic G1 or G2 neuroendocrine tumours of GI or lung Treatment-naïve pts and pre-treated pts (all available treatment options are allowed) with PD
NCT00842348Lanreotide autogel 120 mgSSTRNon-functioning GEP-NETs
NCT00690430Pasireotide LAR 60 mg vs Octreotide LAR 40 mgSSTRMetastatic carcinoid tumours Pts with disease-related symptoms inadequately controlled by somatostatin analogues
NCT00774930Somatuline depot (lanreotide) vs PCBSSTRCarcinoid tumours with liver metastasis Treatment-naïve pts and pts pre-treated with and responsive to somatostatine analogues
NCT00092287Lanreotide autogel vs Sandostatin LARSSTRCarcinoid tumours localized in lung, stomach or midgut Treatment-naïve pts and pts pre-treated with and responsive to somatostatine analogues
NCT00263659Telotristat etiprate (LX1606) vs PBOTPHWell-differentiated metastatic NETs with carcinoid syndrome Treatment-naïve pts
NCT01677910Telotristat etiprate (LX1606) vs PBOTPHWell-differentiated metastatic NETs with carcinoid syndrome Pts with disease-related symptoms inadequately controlled by somatostatin analogues
Table 2 Ongoing phase II trials in gastro-entero-pancreatic neuroendocrine tumours
ClinicalTrials.gov IdentifierInvestigated drugTargetType of enrolled pts
NCT01841736PazopanibVEGFR PDGFR FGFR c-kitProgressive carcinoid tumours
NCT02399215NintedanibVEGFR FGFR PDGFRCarcinoid tumour Metastatic carcinoid tumour Neuroendocrine neoplasm
NCT01994213Famitinibc-kit PDGFR VEGFR FltGastroenteropancreatic neuroendocrine tumour
NCT01121939Bevacizumab plus pertuzumab plus sandostatin LARVEGF HER2Advanced neuroendocrine cancers
NCT02259725Regorafenibc-RAF BRAF VEGFR PDGFRa FGFR-1 c-kit RET Flt-3Gastrinoma Glucagonoma Insulinoma Metastatic gastrointestinal carcinoid tumour Pancreatic polypeptide tumour Pulmonary carcinoid tumour Recurrent gastrointestinal carcinoid tumour Recurrent Islet cell carcinoma Somatostatinoma
NCT01784861X-82 plus everolimusmTORPancreatic neuroendocrine tumours
NCT01508104BEZ235 plus everolimusPI3KAdvanced cancers of different types
NCT00781911CixutumumabIGF-1RNeuroendocrine tumours